Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + apatinib perioperative therapy in locally advanced head and neck squamous cell carcinoma
ChiCTR2500105995Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab and Rivoceranib in head and neck squamous cell carcinoma (HNSCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Major pathological response rate. Started Jul 2025; status: recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500105995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105995.